Epigenomics Signs up Turkish Distributor for Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics said today that it has signed up the biomedical distributor Dateks to market its colorectal cancer test in Turkey.

Epigenomics said that Dateks will market the Epi proColon, a DNA methylation-based test that detects colorectal cancer in blood plasma by identifying the Septin 9 biomarker.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.